Ravi Kumar Goyal

Dr. Ravi Kumar Goyal

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 November 2014 in Lung Cancer
Verified
Journal Article
Closed access
PDF file
KDKeith L. Davis
Keith L. Davis
RGRavi Kumar Goyal
Ravi Kumar Goyal
SAStephen L. Able
Stephen L. Able
JBJacqueline Brown
Jacqueline Brown
LLLi Li
Li Li
JKJames A. Kaye
James A. Kaye

9 February 2023 in Cancer
Verified
Journal Article
Closed access
RGRavi Kumar Goyal
Ravi Kumar Goyal
HCHua Chen
Hua Chen
SASusan M. Abughosh
Susan M. Abughosh
HHHolly M. Holmes
Holly M. Holmes
SCSean D. Candrilli
Sean D. Candrilli
MJMichael L. Johnson
Michael L. Johnson

1 January 2008 in Indian Journal of Pharmacology
Verified
Journal Article
Open access
PDF file
RBRakesh Barik
Rakesh Barik
SJSanjay K. Jain
Sanjay K. Jain
DQDeep Qwatra
Deep Qwatra
AJAmit Joshi
Amit Joshi
GTGirraj Sharan Tripathi
Girraj Sharan Tripathi
RGRavi Kumar Goyal
Ravi Kumar Goyal
The Indian Journal of Pharmacology is an official organ of the Indian Pharmacological Society

1 September 2014 in Health & Place
Verified
Journal Article
Closed access
SWStephanie B Wheeler
Stephanie B Wheeler
TKTzy-Mey Kuo
Tzy-Mey Kuo
RGRavi Kumar Goyal
Ravi Kumar Goyal
AMAnne-Marie Meyer
Anne-Marie Meyer
KLKristen Hassmiller Lich
Kristen Hassmiller Lich
MPMichael P. Pignone
Michael P. Pignone

26 April 2014 in Maternal and Child Health Journal
Verified
Journal Article
Closed access
PDF file
MHMarianne M. Hillemeier
Marianne M. Hillemeier
MDMarisa E. Domino
Marisa E. Domino
RWRebecca Wells
Rebecca Wells
RGRavi Kumar Goyal
Ravi Kumar Goyal
HKHye-Chung Kum
Hye-Chung Kum
ABAnirban Basu
Anirban Basu

29 May 2019 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
SKShaum M. Kabadi
Shaum M. Kabadi
RGRavi Kumar Goyal
Ravi Kumar Goyal
SNSaurabh P. Nagar
Saurabh P. Nagar
JKJames A. Kaye
James A. Kaye
KDKeith L. Davis
Keith L. Davis
Introduction: Contemporary data describing treatment patterns, adverse events (AEs), and outcomes in patients with chronic lymphocytic leukemia (CLL) in clinical practice are lacking. We conducted a retrospective cohort study and assessed treatment patterns, AEs, health‐care resource use (HCRU), and costs in patients with diagnosis of CLL.Methods: Using a nationally representative population of privately insured patients in the US, adult patients with CLL diagnosis (July 2012‐June 2015) were selected if they had continuous health plan enrollment for ≥12 months before the first CLL diagnosis without any evidence of any CLL‐directed treatment. Treatment patterns up to four lines of therapy (LOT) and occurrence of AEs during CLL therapies were assessed. Mean per‐patient monthly HCRU and costs were assessed overall and by number of unique AEs.Results: Of all patients meeting the selection criteria (n = 7,639; median age, 66 years), 18% (n = 1,379) received a systemic therapy during study follow‐up. Of these, bendamustine/rituximab (BR) was the most common first observed regimen (28.1%), while ibrutinib was the most common therapy in the second (20.8%) and third (25.5%) observed regimens. The mean monthly all‐cause and CLL‐related costs, among patients treated with a systemic therapy, were $7,943 (SD = $15,757) and $5,185 (SD = $9,935), respectively. Mean monthly all‐cause costs increased by the number of AEs (from $905 [SD = $1,865] among those with no AEs to $6,032 [SD = $13,290] among those with ≥6 AEs).Conclusions: Chemoimmunotherapy, particularly BR, was the most common first observed therapy for CLL, whereas ibrutinib was most preferred in the second and third observed lines of therapy during the study period. Findings demonstrate that the economic burden of AEs in CLL is substantial.